

# Community interest in predictive genetic testing for susceptibility to major depressive disorder in a large national sample

A. Wilde<sup>1,2\*</sup>, B. Meiser<sup>3</sup>, P. B. Mitchell<sup>1,2,4</sup>, D. Hadzi-Pavlovic<sup>1,2</sup> and P. R. Schofield<sup>4,5,6</sup>

<sup>1</sup> School of Psychiatry, University of New South Wales, Sydney, Australia

<sup>2</sup> Black Dog Institute, Sydney, Australia

<sup>3</sup> Prince of Wales Clinical School, University of New South Wales, Sydney, Australia

<sup>4</sup> Brain Sciences UNSW, Sydney, Australia

<sup>5</sup> Neuroscience Research Australia, Sydney, Australia

<sup>6</sup> School of Medical Sciences, University of New South Wales, Sydney, Australia

**Background.** Despite international concern about unregulated predictive genetic testing, there are surprisingly few data on both the determinants of community interest in such testing and its psychosocial impact.

**Method.** A large population-based public survey with community-dwelling adults ( $n=1046$ ) ascertained through random digit dialling. Attitudes were assessed by structured interviews.

**Results.** The study found strong interest in predictive genetic testing for a reported susceptibility to depression. Once the benefits and disadvantages of such testing had been considered, there was significantly greater interest in seeking such a test through a doctor (63%) compared to direct-to-consumer (DTC; 40%) ( $p<0.001$ ). Personal history of mental illness [odds ratio (OR) 2.58,  $p<0.001$ ], self-estimation of being at higher than average risk for depression (OR 1.92,  $p<0.001$ ), belief that a genetic component would increase rather than decrease stigma (OR 1.62,  $p<0.001$ ), and endorsement of benefits of genetic testing (OR 3.47,  $p<0.001$ ) significantly predicted interest in having such a test.

**Conclusions.** Despite finding attitudes that genetic links to mental illness would increase rather than decrease stigma, we found strong community acceptance of depression risk genotyping, even though a predisposition to depression may only manifest upon exposure to stressful life events. Our results suggest that there will be a strong demand for predictive genetic testing.

Received 13 July 2010; Revised 1 November 2010; Accepted 6 November 2010; First published online 15 December 2010

**Key words:** Direct-to-consumer testing, major depressive disorder, predictive genetic testing, psychiatric genetics, public opinion.

## Introduction

Identifying healthy individuals with genotypes that suggest increased risk of psychiatric illness provides an opportunity to reduce the burden of disease through environment-specific intervention at a pre-symptomatic stage. Heritability estimates of 33–48% provide evidence of a genetic component for major depressive disorder (McGuffin *et al.* 1996; Kendler & Prescott, 1999) whereas lifetime risk for unaffected individuals with a first-degree relative with major depressive disorder is estimated to be 10–25% (Hill & Sahhar, 2006). However, as a complex disorder, the

contribution of any single gene to the causation of depression is likely to be small as additional genetic and environmental risk factors must be taken into account.

Disclosure of genotyping information about risk for major depressive disorder (Wilhelm *et al.* 2009) or Alzheimer's disease (Green *et al.* 2009) to asymptomatic adults has been shown to provide a benefit to individuals with 'low-risk' variants and to cause low to modest distress to those with an 'increased risk' variant. Although most genetic testing is currently available only through a health-care provider, an increasing range of tests are being offered direct-to-consumer (DTC; Hudson *et al.* 2007) without medical supervision, raising concerns about the psychosocial impact of risk disclosure. This has stimulated popular debate about the right-to-know or not to know one's own genetic information, and whether predictive genetic tests, especially those available DTC, provide

\* Address for correspondence: Dr A. Wilde, School of Psychiatry, University of New South Wales, Black Dog Institute Building, Hospital Road, Randwick, NSW, Australia 2031.  
(Email: alex.wilde@unsw.edu.au)

useful information about one's health (Shetty, 2008). Many genetic tests offered DTC involve unreplicated gene-disease associations and have uncertain predictive value and clinical utility (Kraft & Hunter, 2009). Furthermore, without medical supervision, consumers may be at risk of making uninformed health decisions (Cameron *et al.* 2009).

Few data exist on both the determinants of community interest in such testing and its psychosocial impact. Given current international concern about unregulated predictive genetic testing, such data are required urgently to inform national and international policy development.

Previous studies on attitudes towards genetic testing for susceptibility alleles thought to be involved in some mental illnesses have been limited predominantly to preliminary and/or qualitative studies involving people with an unspecified psychiatric diagnosis (Laegsgaard & Mors, 2008), people with multiple relatives affected by bipolar disorder (Smith *et al.* 1996; Trippitelli *et al.* 1998; Jones *et al.* 2002; Meiser *et al.* 2005, 2008) or schizophrenia (Austin *et al.* 2006; DeLisi & Bertisch, 2006), and psychiatrists (Smith *et al.* 1996; Jones *et al.* 2002; DeLisi & Bertisch, 2006). These studies have generally found positive attitudes towards predictive genetic testing for predisposition to psychiatric disorders. One recent quantitative study involving families with a high density of bipolar disorder showed that interest in hypothetical genetic testing increased with the degree of certainty indicated by the test (Meiser *et al.* 2008). Further studies reported strong support for predictive genetic testing for predisposition to psychiatric disorders but were limited to people with a diagnosis of major depressive disorder, bipolar disorder, schizophrenia and/or anxiety disorders participating in psychiatric genetic studies (Illes *et al.* 2003; Laegsgaard *et al.* 2009). Our previous qualitative study found positive public interest in depression risk genotyping, which was negatively influenced by the potential for discrimination and loss of privacy (Wilde *et al.* 2010). Participants showed trust in obtaining such a test through the medical system but were wary of DTC genetic testing services.

The present investigation is the first national population study to examine this issue for genetic variations associated with mental health in general. This study uses the hypothetical example of serotonin transporter genotyping as it has been previously reported to convey a gene-environment risk for major depressive disorder (Caspi *et al.* 2003; Eley *et al.* 2004; Kaufman *et al.* 2004; Kendler *et al.* 2005; Taylor *et al.* 2006; Wilhelm *et al.* 2006).

The present study proposes the following hypotheses: interest in predictive testing for a depression-risk

genotype will be (i) greater if available from a doctor rather than DTC on the internet; and will be positively associated with (ii) having a personal history of mental illness and (iii) lower perceived social stigma attached to mental illness.

## Method

Participants across Australia were recruited by a contracted market research company in May 2008 using random digit dialling of a computer-generated list of landline telephone numbers that use prefixes based on the geographic coverage of the sample's area, with the aim of producing a nationally representative sample. Respondents were selected from each household using a Computer Assisted Telephone Interviewing (CATI)-generated algorithm. Only those aged  $\geq 18$  years and fluent in English were eligible to participate. Only one individual per household could participate. The interviews were completed until a target sample size of at least 1000 was reached. Ethical approval for the study was provided by the relevant Institutional Review Board.

## Measures

### *Demographic characteristics*

Data on sex, age, highest level of education achieved, current marital status and country of birth were collected using specifically designed multiple-choice items.

### *Clinical and family history data*

Data on self-estimation of risk of depression were collected in a three-part question early in the survey: 'Compared with the average person, would you say your risk of depression is higher than average; lower than average; the same as the average person?'

Self-reported data on personal history of mental illness and exposure to mental illness through close relatives or close friends were collected on completion of the survey. Participants were asked 'have you or has a close relative or friend ever been diagnosed with depression, bipolar disorder or schizophrenia?' These terms were defined to participants.

### *Causal attributions for mental illness*

Causal attributions to assess the perceived importance of different factors in causing a mental illness were derived from Meiser *et al.* (2007). Participants responded to all items using a five-point Likert-type scale ranging from 1 'not at all important' to 5 'extremely important'. For statistical analysis, items were




Fig. 1. Percentages of participants indicating agreement or strong agreement with a range of perceived benefits and disadvantages of depression-risk genotyping (maximum  $n = 1046$ ).

grouped according to the exploratory factor analysis of Meiser *et al.* (2007), which yielded a four-factor solution with good internal consistency with item groupings representing (i) genetics, (ii) life stress, (iii) abuse and (iv) family environment.

Three items with five-point Likert-type response options were used to assess the degree of endorsement of perceptions about: gene–environment interactions as a causal mechanism (framed as ‘mental illnesses are caused by an interplay of genetic risk and stressful life experiences’), incomplete penetrance as a mechanism of inheritance (framed as ‘it is possible to have a genetic risk for a mental illness but never actually get the disorder’) and no causal genetic factors (framed as ‘it is possible to have a mental illness without a genetic risk’).

### Stigma

Perceptions about the impact of evidence for a genetic component for mental illness on stigma were explored using a three-point scale: ‘stigma would decrease’, ‘a genetic basis for a mental illness would make no difference to stigma’, and ‘stigma would increase’.

### Perceived benefits and disadvantages

Perceived benefits and disadvantages of predictive genetic testing were assessed using 12 items (see Fig. 1 for item wording) with five-point Likert-type response options ranging from 1 (‘strongly disagree’) to 5 (‘strongly agree’). The measure is based on the results of our qualitative study, which explored the range of

perceived benefits and limitations of genetic testing for major depressive disorder (Wilde *et al.* 2010). These measures demonstrated good internal consistency in the present samples, with Cronbach’s  $\alpha = 0.65$  (benefits) and 0.76 (disadvantages). Summary scores were calculated for perceived benefits and disadvantages separately, with higher values indicating greater endorsement of perceived benefits or disadvantages.

### Outcome variable: interest in having genetic testing for depression risk

Data on interest in predictive genetic testing were collected by (i) channel of access (i.e. through a doctor or DTC) and (ii) before and after participants were asked about perceived benefits and disadvantages of predictive testing. The latter two are reported as ‘naïve interest’ and ‘considered interest’ respectively. This produced four variables: naïve interest in having the test through a doctor; naïve interest in having the test DTC; considered interest in having the test through a doctor; and considered interest in having the test DTC. Interest in having depression risk testing was assessed by one item with four Likert-type response options ranging from ‘no, definitely not’, ‘no, probably not’, ‘yes, probably’, to ‘yes, definitely’ plus ‘don’t know’.

Questions were framed as: ‘If a genetic test to determine your risk for developing depression in the event of experiencing stressful life events was available through (1) your own doctor, (2) via the internet

directly to you from an overseas laboratory, would you be interested in having it?’

As the public health system is likely to be a future provider of predictive genetic testing to informed patients, ‘considered interest in genetic testing through a doctor’ was selected as the most appropriate outcome variable for the purposes of multivariate analyses. This variable was recoded into a binary variable by merging the ‘definitely’ and ‘probably’ options and redefining the new variable as ‘yes, would consider’ versus ‘no, would not consider’ genetic testing. ‘Don’t know’ responses were not included in the new variable.

### Statistical analyses

Data were explored initially with descriptive statistics.  $\chi^2$  cross-tabulations were analysed for naïve and considered interest through a doctor and through DTC channels. Bivariate associations between possible predictor variables and the outcome variable were first examined using an independent samples *t* test for continuous predictor variables, Mann–Whitney *U* tests for ordinal predictor variables and Pearson’s  $\chi^2$  cross-tabulations for categorical predictors. All variables with a bivariate association with  $p < 0.1$  were entered into a backward stepwise removal regression model until the only remaining variables were those with  $p < 0.05$ .

The following variables were assessed as possible predictor variables in the analysis of considered interest in depression-risk testing through accredited medical services: personal history of a mental illness, experience of a mental illness through a close relative or close friend, self-estimation of risk for major depressive disorder, causal attributions for mental illness, gene–environment interaction as a causal mechanism, incomplete penetrance as a hereditary mechanism, no causal genetic factors, perceived impact of a genetic component for mental illness on social stigma, and perceived benefits and disadvantages of having such a genetic test. All regression analyses were adjusted for age, sex, education level and country of birth.

## Results

### Participant characteristics

Of the 1544 eligible individuals contacted, 498 declined, resulting in 1046 completed surveys and a participation rate of 68%. Sociodemographic characteristics of the participants are presented in Table 1. Sixty-one per cent were female and 39% male compared to 50.2% and 49.8% respectively in the Australian adult resident population. The mean age of participants was 50.7 years [95% confidence interval

**Table 1.** Summary of participant characteristics (maximum  $n = 1046$ )

Sex	
Male	409 (39.1)
Female	637 (60.9)
Age [mean (s.d.) = 50.7 years (16.2), range 18–88]	
18–29	111 (10.6)
30–39	169 (16.2)
40–49	221 (21.1)
50–59	212 (20.3)
$\geq 60$	330 (31.6)
Current marital status	
Married/ <i>de facto</i>	661 (63.2)
Other	384 (36.8)
Country of birth	
Australia	815 (78.0)
Outside Australia (49 countries)	230 (22.0)
Highest level of education	
No post-school education	473 (45.4)
Post-school education	569 (54.6)
History of mental illness	
Personal <sup>a</sup>	
Yes	237 (22.7)
No	805 (77.3)
Close relative/friend <sup>b</sup>	
Yes	661 (63.7)
No	337 (36.3)
Self-estimation of risk for major depressive disorder <sup>c</sup>	
Higher than average	240 (23.2)
Lower than average	295 (28.5)
Same as average	500 (48.3)

s.d., Standard deviation.

Values are given as  $n$  (%).

<sup>a</sup> Refers to personal history of depression, bipolar disorder or schizophrenia.

<sup>b</sup> Refers to experience of depression, bipolar or schizophrenia through a close relative or close friend.

<sup>c</sup> Refers to personal estimation of risk for major depressive disorder compared to average population risk.

(CI) 49.7–51.7, range 18–88 years], compared to a mean of 47.0 years among the resident Australian population aged  $\geq 18$  years. Twenty-two per cent (95% CI 22–25) were born overseas, compared to an estimated 25% of the resident population of Australia born overseas (Australian Bureau of Statistics, 2006).

### Perceived benefits and disadvantages of predictive genetic testing for depression risk

Figure 1 details the proportions of participants who agreed or strongly agreed with a range of perceived benefits and disadvantages of genetic testing.

**Table 2(a).** Items assessed for association with considered interest<sup>a</sup> in depression-risk genotyping (maximum  $n = 1046$ )

Variable	Interested in testing <sup>a</sup>			
	$n$	%	$\chi^2$	$p$
Sex				
Male	234	58.1		
Female	410	65.5	5.78	0.016 <sup>f</sup>
Highest level of education				
No post-school education	309	66.6	5.68	0.017 <sup>f</sup>
Post-school education	333	59.4		
History of mental illness				
Personal <sup>b</sup>				
Yes	189	81.8	46.4	<0.001 <sup>f</sup>
No	455	57.3		
Close relative/friend <sup>c</sup>				
Yes	402	62.0		
No	239	64.1	0.42	0.52
Self-estimation of risk for major depressive disorder <sup>d</sup>				
Higher than average	182	77.1	61.63	<0.001 <sup>f</sup>
Same as average	324	66.1		
Lower than average	132	45.2		
Beliefs about social stigma <sup>e</sup>				
Genetic component increases stigma	338	70.9	29.22	<0.001 <sup>f</sup>
No effect on stigma	153	54.6		
Genetic component decreases stigma	98	52.7		

<sup>a</sup> Refers to considered interest in genetic testing through a medical clinic.

<sup>b</sup> Refers to personal history of a mental illness (depression, bipolar disorder or schizophrenia).

<sup>c</sup> Refers to experience of depression, bipolar or schizophrenia through a close relative or close friend.

<sup>d</sup> Refers to personal estimation of risk for major depressive disorder compared to average population risk.

<sup>e</sup> Refers to belief that genetic evidence for mental illness would increase or decrease stigma.  $\chi^2$  values are from Pearson's  $\chi^2$  tests.

<sup>f</sup>  $p$  values <0.1 entered into logistic regression.

### **Interest in predictive genetic testing for depression risk by channel of access**

Interest in depression-risk genotyping varied according to channel of access (doctor *versus* DTC on the internet) and before *versus* after consideration of positive and negative implications, information about which was provided during the telephone interview ('naïve interest' *versus* 'considered interest'). When naïve, 60% of participants were interested in depression-risk genotyping through a doctor, which marginally increased to 63% after consideration. When naïve, 49% of participants were interested in accessing the same test DTC on the internet, which significantly decreased to 40% once given the opportunity for consideration ( $n = 981$ ,  $\chi^2 = 476$ ,  $df = 1$ ,  $p < 0.001$ ). Interest in accessing depression-risk genotyping through a doctor was

significantly greater than interest accessing such a test DTC in both cases, when either naïve ( $p < 0.001$ ) or considered ( $p < 0.001$ ).

### **Factors associated with considered interest in predictive genetic testing for depression risk**

Table 2 shows the results from bivariate analyses of factors associated with considered interest in depression-risk genotyping. Considered interest in depression-risk genotyping was significantly and positively associated with having a personal history of a mental illness; self-estimation of having a higher than average risk for major depressive disorder; being female; having no post-school education; endorsement of perceived benefits of having such a test; perceiving genetics, life stress and/or abuse as causal attributions

**Table 2(b).** Items assessed for association with considered interest<sup>a</sup> in depression-risk genotyping (maximum  $n=1046$ )

Variable	Interested in testing <sup>a</sup>		Not interested in testing <sup>a</sup>		z/t	p
	n	Mean (s.d.)	n	Mean (s.d.)		
Endorsement of benefits or disadvantages of testing <sup>b</sup>						
Endorse benefits	644	4.1 (0.5)	385	3.8 (0.7)	8.35	<0.001 <sup>d</sup>
Endorse disadvantages	644	3.4 (0.8)	385	3.5 (0.8)	1.83	0.068 <sup>d</sup>
Endorsement of causal attributions <sup>b</sup>						
Genetics	644	4.5 (0.9)	385	4.5 (1.0)	2.15	0.032 <sup>d</sup>
Abuse	644	4.6 (0.6)	385	4.4 (0.8)	5.16	<0.001 <sup>d</sup>
Life stress	644	3.7 (0.8)	385	3.9 (1.0)	5.15	<0.001 <sup>d</sup>
Family environment	644	4.1 (0.9)	385	3.8 (1.0)	4.86	<0.001 <sup>d</sup>
Gene–environment interaction	618	4.1 (0.7)	368	3.9 (0.8)	2.23	0.026 <sup>d</sup>
Incomplete penetrance	597	4.0 (0.8)	359	3.9 (0.8)	1.18	0.238
No genetic factors	604	4.1 (0.8)	368	4.1 (0.7)	0.77	0.439
Age	643	50.5 (16.7)	384	50.9 (15.5)	0.39 <sup>c</sup>	0.694

s.d., Standard deviation.

<sup>a</sup> Refers to considered interest in genetic testing through a medical clinic.

<sup>b</sup> Range 1 to 5, with higher values indicating greater endorsement. Values are absolute values from Mann–Whitney *U* tests.

<sup>c</sup> *t* value is from an independent samples *t* test.

<sup>d</sup> *p* values <0.1 entered into logistic regression.

**Table 3.** Final model of logistic regression analysis predicting factors influencing interest<sup>a</sup> in having depression-risk genotyping after controlling for demographic factors ( $n=930$ )

Variable	B	OR	95% CI	p
Personal history of mental illness	0.95	2.58	1.66–4.00	<0.001
Self-estimation of risk for depression higher than average	0.65	1.92	1.52–2.42	<0.001
Endorsement of perceived benefits of depression-risk genotyping	1.24	3.47	2.57–4.66	<0.001
Endorsement of perceived disadvantages of depression-risk genotyping	–0.23	0.80	0.66–0.97	0.021
Belief that genetic evidence for mental illness will increase social stigma	0.48	1.62	1.34–1.96	<0.001
Age	–0.01	0.99	0.98–1.00	0.057
Sex	0.22	1.25	0.92–1.70	0.152
Education level	–0.183	0.83	0.61–1.14	0.249
Country of birth	–0.12	0.89	0.62–1.27	0.523

OR, Odds ratio; CI, confidence interval.

Final model:  $-2 \log$  likelihood ratio = 1030.679, Cox and Snell  $R^2=0.189$ , Nagelkerke  $R^2=0.258$ ,  $p<0.001$ .

<sup>a</sup> Refers to considered interest in genetic testing through a medical clinic.

for mental illness; and perceiving gene–environment interaction as a causal mechanism. Among participants who thought evidence of a genetic component would affect stigma associated with mental illness, a significantly greater proportion believed stigma would increase rather than decrease ( $n=670$ , 72% *v.* 28%,  $p<0.001$ ). Despite this, we found that considered interest in having depression-risk genotyping was significantly associated with beliefs that social stigma would increase.

When these variables were entered into a logistic regression model using a backward stepwise (likelihood ratio) elimination method (Table 3), personal history

of mental illness [odds ratio (OR) 2.58,  $p<0.001$ ], higher than average self-estimation of risk for major depressive disorder (OR 1.92,  $p<0.001$ ), endorsement of benefits of testing for a depression-risk variant (OR 3.47,  $p<0.001$ ), and the belief that genetic evidence for mental illness would increase social stigma (OR 1.62,  $p<0.001$ ) were all significantly and positively associated with considered interest in depression-risk genotyping after controlling for sex, age, education level and country of birth. A significant negative predictor of interest was endorsement of perceived disadvantages of depression-risk genotyping (OR 0.80,  $p=0.021$ ).

## Discussion

This large, national population-based study suggests that formal medical services are likely to be the preferred channel for accessing predictive genetic testing as demonstrated in this example of serotonin transporter genotyping for depression risk. This preference was significantly higher compared to interest in accessing genetic tests DTC after considering the benefits and disadvantages of predictive genetic testing. Nevertheless, considered interest in accessing such a test commercially prevailed, suggesting that concerns about the availability of unregulated DTC genetic testing need to be addressed. This finding supports results of our previous qualitative study, which demonstrated greater trust among participants in obtaining such a test through the medical system, with interest modified by concerns about genetic discrimination and loss of privacy (Wilde *et al.* 2010).

Of the 1029 participants who answered the question, 63% indicated considered interest in having predictive genetic testing for susceptibility to depression, if it were available. This level of interest is similar or marginally lower than that reported in previous studies that have demonstrated rates of interest in predictive genetic testing of 61% (Green *et al.* 2009), 69% (Jones *et al.* 2002), 83% (DeLisi & Bertisch, 2006; Laegsgaard *et al.* 2009) and 97% (Smith *et al.* 1996) for susceptibility to Alzheimer's disease, bipolar disorder (Smith *et al.* 1996; Trippitelli *et al.* 1998; Jones *et al.* 2002; Meiser *et al.* 2008), schizophrenia (Austin *et al.* 2006; DeLisi & Bertisch, 2006) and psychiatric disorders in general (Illes *et al.* 2003; Laegsgaard & Mors, 2008; Laegsgaard *et al.* 2009) in relatively small groups with direct experience of the illness including patients, relatives and professionals. The lower rate of interest demonstrated in this large national sample is likely to reflect a more realistic indication of community interest in predictive genetic testing for depression risk and other psychiatric conditions. Actual uptake of such testing once clinically available could be lower than predicted by intention to test (Lerman *et al.* 2002).

The present study identified strong positive significant associations between considered interest in genetic testing for susceptibility to depression and personal self-reported history of mental illness; a higher than average self-estimation of increased risk for major depressive disorder; endorsement of the perceived benefits of having such a test; and a belief that a genetic explanation for mental illness would increase social stigma linked with the disorder. These associations were independent of age, sex, level of education and country of birth.

The finding that perceived personal susceptibility to the disorder is a strong predictor of interest in

predictive genetic testing is consistent with that reported for other multifactorial disorders such as heart disease (Sanderson *et al.* 2004), schizophrenia (DeLisi & Bertisch, 2006), bipolar disorder (Trippitelli *et al.* 1998; Jones *et al.* 2002; Meiser *et al.* 2008) and psychiatric disorders in general (Laegsgaard & Mors, 2008). However, predictors of uptake of predictive genotyping in clinical situations may differ. Uptake rates are likely to be influenced by differences in patient perceptions about predictive validity of the genetic test in question; potential benefits of such a genetic test, such as accessing early help; potential disadvantages such as employment and insurance discrimination; and differences in implications for members of affected families.

The finding of a significant positive association between considered interest in genetic testing for susceptibility to depression and endorsement of perceived benefits of having such a test, and a significant negative association with endorsement of perceived disadvantages, supports prevailing beliefs that perceived benefits may outweigh risks (Trippitelli *et al.* 1998). The most frequently rated perceived benefits, namely a greater preparedness for accessing early psychological help and minimizing stress, are consistent with beliefs reported in a previous study that such testing could facilitate prevention and earlier intervention of major depressive disorder (Wilhelm *et al.* 2009). The findings also confirmed perceptions that potential for discrimination by insurance companies or employers was the most frequently identified disadvantage of genetic testing for susceptibility to depression. Several governments have issued a ban on marketing genetic tests for common complex disorders directly to the consumer in the absence of appropriate regulation (ALRC, 2003; Hudson *et al.* 2007; Human Genetics Commission UK, 2007). Despite the signing of the Genetic Information Nondiscrimination Act (GINA) into law in 2008 in the USA, where many of the commercial vendors of DTC genetic tests are based, there may be no guarantees of protection against discrimination (Van Hoyweghen & Horstman, 2008). Considering DTC genetic tests are marketed internationally, consumers may have no legal protection from genetic discrimination for insurance or employment in their own country. The recent proposal to introduce a mandatory registry of genetic tests aims to overcome some of these problems and improve the genetic testing system by providing the public and health providers with accurate, reliable and validated information about the options available before decisions are made about obtaining a genetic test (Zonno & Terry, 2009). Thus, the study's findings highlight that, although predictive genetic testing as an intervention tool for target groups is likely to be

acceptable to the general community, they indicate the need for appropriate legislation to prevent genetic discrimination if such interventions are to be effective.

Finding a significant positive association between beliefs that evidence of a genetic component for mental illness would increase rather than decrease social stigma and considered interest in having genetic testing for susceptibility to depression seems surprising at first. It could be that perceived benefits of genetic testing outweigh concerns about stigma, that major depressive disorder is perceived as less likely to have a genetic basis than other mental illnesses, or that there is less stigma attached to depression than bipolar disorder and schizophrenia.

It should be noted that the use of landline telephone numbers may have skewed the sample towards older age groups and females, consistent with reported participation bias in public health surveys (Purdie et al. 2002; Sogaard et al. 2004). The present study used strategies known to minimize self-selection bias caused by non-response, including randomization of participant selection per household, achieving a moderately high participation rate, and controlling the results for demographic confounders statistically (Mishra et al. 1993).

Other limitations relate to the possibility that some participants may have interpreted the term 'life stress' to mean everyday life stress rather than significant stressors associated with mental illness, such as child abuse, which could have affected interest in testing based on perceptions about the modifiable nature of risk factors. Attitudes towards genetic testing for susceptibility to a psychiatric disorder may be influenced by naivety about the low predictive power of such tests. The low risk rates for first-degree relatives for developing psychiatric disorders with incomplete penetrance compared with Mendelian traits should be kept in perspective when informing the public and designing mental health interventions.

## Conclusions

This is the first study to provide data from a large national cohort in which the determinants of community interest in predictive genetic testing for mental illness and its psychosocial impacts have been investigated. Using the example of testing for a genetic variant for depression risk, the results indicate that there is likely to be strong interest in predictive genetic testing for a complex trait such as major depressive disorder if it were to become available, even though the predictive validity and clinical utility of such tests remain unclear. It is likely that interest will persist despite finding attitudes that genetic links to mental illness would increase rather than decrease stigma.

The study provides objective data in place of the current subjective commentaries on community concern about unregulated predictive genetic testing. Large population surveys such as that reported here are important in informing public debate, public education programmes and policymaking.

## Acknowledgements

This study was supported by an Australian National Health and Medical Research Council (NHMRC) Public Health Ph.D. scholarship (455414), Career Development Award (350989), Program Grant (510135) and Project Grant (510216); and by the University of New South Wales. We thank the study participants who answered the survey.

## Declaration of Interest

None.

## References

- Austin JC, Smith G, Honer WG (2006). The genomic era and perceptions of psychotic disorders: genetic risk estimation, associations with reproductive decisions and views about predictive testing. *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics* **141B**, 926–928.
- Australian Bureau of Statistics (2006). *Census of Population and Housing Cat. No. 2068.0 - Census Tables*. Australian Bureau of Statistics: Canberra.
- Australian Law Reform Commission, National Health and Medical Research Council (Australia) & Australian Health Ethics Committee (2003). *Essentially Yours: The Protection of Human Genetic Information in Australia*. Australian Law Reform Commission: Sydney, NSW.
- Cameron LD, Sherman KA, Marteau TM, Brown PM (2009). Impact of genetic risk information and type of disease on perceived risk, anticipated affect, and expected consequences of genetic tests. *Health Psychology* **28**, 307–316.
- Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science* **301**, 386–389.
- DeLisi LE, Bertisch H (2006). A preliminary comparison of the hopes of researchers, clinicians, and families for the future ethical use of genetic findings on schizophrenia. *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics* **141**, 110–115.
- Eley TC, Sugden K, Corsico A, Gregory AM, Sham P, McGuffin P, Plomin R, Craig IW (2004). Gene-environment interaction analysis of serotonin system markers with adolescent depression. *Molecular Psychiatry* **9**, 908–915.
- Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA, for the



- REVEAL Study Group** (2009). Disclosure of APOE genotype for risk of Alzheimer's disease. *New England Journal of Medicine* **361**, 245–254.
- Hill MK, Sahhar M** (2006). Genetic counselling for psychiatric disorders. *Medical Journal of Australia* **185**, 507–510.
- Hudson K, Javitt G, Burke W, Byres P** (2007). ASHG statement on direct-to-consumer genetic testing in the United States. *American Journal of Human Genetics* **81**, 635–637.
- Human Genetics Commission UK** (2007). More Genes Direct: a report on developments in the availability, marketing and regulation of genetic tests supplied directly to the public. **Department of Health**: UK.
- Illes F, Rietz C, Fuchs M, Ohiraun S, Prell K, Rudinger G, Maier W, Rietschel M** (2003). Attitudes towards psychiatric genetic research and predictive testing: hopes and fears of patients, relatives and the general population in Germany [in German]. *Ethik in der Medizin* **15**, 268–281.
- Jones I, Scourfield J, McCandless F, Craddock N** (2002). Attitudes towards future testing for bipolar disorder susceptibility genes: a preliminary investigation. *Journal of Affective Disorders* **71**, 189–193.
- Kaufman J, Yang B-Z, Douglas-Palumberi H, Houshyar S, Lipschitz D, Krystal JH, Gelernter J** (2004). Social supports and serotonin transporter gene moderate depression in maltreated children. *Proceedings of the National Academy of Sciences USA* **101**, 17316–17321.
- Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B** (2005). The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. *Archives of General Psychiatry* **62**, 529–535.
- Kendler KS, Prescott CA** (1999). A population-based twin study of lifetime major depression in men and women. *Archives of General Psychiatry* **56**, 39–44.
- Kraft P, Hunter DJ** (2009). Genetic risk prediction – are we there yet? *New England Journal of Medicine* **360**, 1701–1703.
- Laegsgaard MM, Kristensen AS, Mors O** (2009). Potential consumers' attitudes toward psychiatric genetic research and testing and factors influencing their intentions to test. *Genetic Testing and Molecular Biomarkers* **13**, 57–65.
- Laegsgaard MM, Mors O** (2008). Psychiatric genetic testing: attitudes and intentions among future users and providers. *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics* **147B**, 375–384.
- Lerman C, Croyle R, Tercyak K, Hamann H** (2002). Genetic testing: psychological aspects and implications. *Journal of Consulting and Clinical Psychology* **70**, 784–797.
- McGuffin P, Katz R, Watkins S, Rutherford J** (1996). A hospital-based twin register of the heritability of DSM-IV unipolar depression. *Archives of General Psychiatry* **53**, 129–136.
- Meiser B, Kasparian NA, Mitchell PB, Strong K, Simpson JM, Tabassum L, Mireskandari S, Schofield PR** (2008). Attitudes to genetic testing in families with multiple cases of bipolar disorder. *Genetic Testing* **12**, 233–244.
- Meiser B, Mitchell P, Kasparian NA, Strong K, Simpson JM, Mireskandari S, Tabassum L, Schofield P** (2007). Attitudes towards childbearing, causal attributions for bipolar disorder and psychological distress: a study of families with multiple cases of bipolar disorder. *Psychological Medicine* **37**, 1601–1611.
- Meiser B, Mitchell PB, McGirr H, van Herten M, Schofield PR** (2005). Implications of genetic risk information in families with a high density of bipolar disorder: an exploratory study. *Social Science and Medicine* **60**, 109–118.
- Mishra SI, Dooley D, Catalano R, Serxner S** (1993). Telephone health surveys: potential bias from noncompletion. *American Journal of Public Health* **83**, 94–99.
- Purdie DM, Dunne MP, Boyle FM, Cook MD, Najman JM** (2002). Health and demographic characteristics of respondents in an Australian national sexuality survey: comparison with population norms. *Journal of Epidemiology and Community Health* **56**, 748–753.
- Sanderson SC, Wardle J, Jarvis MJ, Humphries SE** (2004). Public interest in genetic testing for susceptibility to heart disease and cancer: a population-based survey in the UK. *Preventive Medicine* **39**, 458–464.
- Shetty P** (2008). Home DNA test kits cause controversy. *Lancet* **371**, 1739–1740.
- Smith LB, Sapers B, Reus VI, Freimer NB** (1996). Attitudes towards bipolar disorder and predictive genetic testing among patients and providers. *Journal of Medical Genetics* **33**, 544–549.
- Sogaard A, Selmer R, Bjertness E, Thelle D** (2004). The Oslo Health Study: the impact of self-selection in a large, population-based survey. *International Journal for Equity in Health* **3**, 3.
- Taylor SE, Way BM, Welch WT, Hilmert CJ, Lehman BJ, Eisenberger NI** (2006). Early family environment, current adversity, the serotonin transporter promoter polymorphism, and depressive symptomatology. *Biological Psychiatry* **60**, 671–676.
- Trippitelli CL, Jamison KR, Folstein MF, Bartko JJ, Depaulo JR** (1998). Pilot study on patients' and spouses' attitudes toward potential genetic testing for bipolar disorder. *American Journal of Psychiatry* **155**, 899–904.
- Van Hoyweghen I, Horstman K** (2008). European practices of genetic information and insurance: lessons for the Genetic Information Nondiscrimination Act. *Journal of the American Medical Association* **300**, 326–327.
- Wilde A, Meiser B, Mitchell PB, Schofield PR** (2010). Public interest in predictive genetic testing, including direct-to-consumer testing, for susceptibility to major depression: preliminary findings. *European Journal of Human Genetics* **18**, 47–51.
- Wilhelm K, Meiser B, Mitchell PB, Finch AW, Siegel J, Parker G, Schofield PR** (2009). Issues concerning feedback to participants about their serotonin transporter genotype and risks for depression. *British Journal of Psychiatry* **194**, 404–410.
- Wilhelm K, Mitchell PB, Niven H, Finch A, Wedgwood L, Scimone A, Blair IP, Parker G, Schofield PR** (2006). Life events, first depression onset and the serotonin transporter gene. *British Journal of Psychiatry* **188**, 210–215.
- Zonno KD, Terry SF** (2009). Registry of genetic tests: a critical stepping stone to improving the genetic testing system. *Genetic Testing and Molecular Biomarkers* **13**, 153–154.